Signadori Bio Raises €11 Million Seed Round to Advance Next-Generation Solid Tumour Platform with Taiho Ventures, Sofinnova Partners, and Invivo Partners.
Amount Raised
€11.1 Million
Round Type
Seed
ParisBiotechnologyTherapeuticsBiopharmaInvestors
Description
Signadori Bio SAS has successfully completed its seed extension financing round, raising a total of €11.1 million. This funding will support the advancement of its lead immunotherapy program SiB-2101 and the development of its proprietary platform. The investment included participation from Taiho Ventures and existing investors. This milestone will help drive the company closer to clinical trials and enhance its operational capabilities.
Who to call at Signadori Bio, and when
A new round usually means Signadori Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Signadori Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Signadori Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Signadori Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Signadori Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Signadori Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.